From monoclonal antibodies (mAb) to recombinant proteins ... biologics offers a cost-effective solution. The market for ‘biosimilars’ is booming in China and across the world.

The US Food and Drug Administration has unveiled its long-awaited draft guidelines on so-called "biosimilar" drugs, generics that mimic the action of biological drugs like enzymes and antibodies.

Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

“With CHMP approvals, Celltrion solidifies its leadership in the European biosimilar market, offering one of the most extensive antibody biosimilar portfolios,” said Celltrion Vice President ...

Antidrug antibodies may interfere with the efficacy of these agents. Future therapies will hopefully include cheaper biosimilars, which have only been recently become available in some countries.

positioning Amneal to have a portfolio of six biosimilars across eight product presentations by 2027. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for ...

FYB202/Otulfi® (ustekinumab-aauz), a biosimilar to Stelara®, launched ... Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play ...

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...